Research programme: cell-based therapeutics - Tenpoint Therapeutics
Latest Information Update: 04 Sep 2023
At a glance
- Originator Tenpoint Therapeutics
- Class Eye disorder therapies; Induced pluripotent stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Eye disorders